Cargando…

Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma

The increasing morbidity and high mortality of intrahepatic cholangiocarcinoma (ICC) has led to the urgent need for new diagnostics and therapeutics. Liver kinase B1 (LKB1) exerts a tumor suppressor role in multiple malignances, while its regulatory role in exosomes secreted by ICC cells is obscure....

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhuo, Zhou, Kunyan, Zeng, Jian, Zhou, Xin, Li, Huanyu, Peng, Ke, Liu, Xiang, Li, Feng, Jiang, Bin, Zhao, Ming, Ma, Tiexiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350976/
https://www.ncbi.nlm.nih.gov/pubmed/35856436
http://dx.doi.org/10.3892/or.2022.8367
_version_ 1784762336436813824
author Liu, Zhuo
Zhou, Kunyan
Zeng, Jian
Zhou, Xin
Li, Huanyu
Peng, Ke
Liu, Xiang
Li, Feng
Jiang, Bin
Zhao, Ming
Ma, Tiexiang
author_facet Liu, Zhuo
Zhou, Kunyan
Zeng, Jian
Zhou, Xin
Li, Huanyu
Peng, Ke
Liu, Xiang
Li, Feng
Jiang, Bin
Zhao, Ming
Ma, Tiexiang
author_sort Liu, Zhuo
collection PubMed
description The increasing morbidity and high mortality of intrahepatic cholangiocarcinoma (ICC) has led to the urgent need for new diagnostics and therapeutics. Liver kinase B1 (LKB1) exerts a tumor suppressor role in multiple malignances, while its regulatory role in exosomes secreted by ICC cells is obscure. In the present study, exosomes were extracted from cell culture supernatants of RBE and HCCC-9810 ICC cells as well as plasma of patients with ICC by ultracentrifugation and the morphology of exosomes was identified by transmission electron microscopy. Notably, compared with that of intracellular LKB1, the protein level of exosomal LKB1 was decreased. Silencing intracellular LKB1 increased the protein levels of programmed death ligand 1 (PD-L1), Slug and phosphorylated-AKT in exosomes, accompanied by decreased expression levels of exosomal LKB1. Exosomes with lower protein levels of LKB1 promoted the expression of the immune checkpoint PD-L1, malignant phenotypes of ICC cells in vitro, and cancer metastasis in vivo. Moreover, the low level of exosomal LKB1 in plasma was tightly associated with the poor prognosis of patients with ICC. Collectively, exosomal LKB1 inhibits the immune checkpoint PD-L1 and metastasis of ICC cells. These findings may provide new methods for the diagnosis and immune therapy of ICC.
format Online
Article
Text
id pubmed-9350976
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-93509762022-08-09 Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma Liu, Zhuo Zhou, Kunyan Zeng, Jian Zhou, Xin Li, Huanyu Peng, Ke Liu, Xiang Li, Feng Jiang, Bin Zhao, Ming Ma, Tiexiang Oncol Rep Articles The increasing morbidity and high mortality of intrahepatic cholangiocarcinoma (ICC) has led to the urgent need for new diagnostics and therapeutics. Liver kinase B1 (LKB1) exerts a tumor suppressor role in multiple malignances, while its regulatory role in exosomes secreted by ICC cells is obscure. In the present study, exosomes were extracted from cell culture supernatants of RBE and HCCC-9810 ICC cells as well as plasma of patients with ICC by ultracentrifugation and the morphology of exosomes was identified by transmission electron microscopy. Notably, compared with that of intracellular LKB1, the protein level of exosomal LKB1 was decreased. Silencing intracellular LKB1 increased the protein levels of programmed death ligand 1 (PD-L1), Slug and phosphorylated-AKT in exosomes, accompanied by decreased expression levels of exosomal LKB1. Exosomes with lower protein levels of LKB1 promoted the expression of the immune checkpoint PD-L1, malignant phenotypes of ICC cells in vitro, and cancer metastasis in vivo. Moreover, the low level of exosomal LKB1 in plasma was tightly associated with the poor prognosis of patients with ICC. Collectively, exosomal LKB1 inhibits the immune checkpoint PD-L1 and metastasis of ICC cells. These findings may provide new methods for the diagnosis and immune therapy of ICC. D.A. Spandidos 2022-07-15 /pmc/articles/PMC9350976/ /pubmed/35856436 http://dx.doi.org/10.3892/or.2022.8367 Text en Copyright: © Liu et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Liu, Zhuo
Zhou, Kunyan
Zeng, Jian
Zhou, Xin
Li, Huanyu
Peng, Ke
Liu, Xiang
Li, Feng
Jiang, Bin
Zhao, Ming
Ma, Tiexiang
Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma
title Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma
title_full Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma
title_fullStr Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma
title_full_unstemmed Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma
title_short Liver kinase B1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma
title_sort liver kinase b1 in exosomes inhibits immune checkpoint programmed death ligand 1 and metastatic progression of intrahepatic cholangiocarcinoma
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9350976/
https://www.ncbi.nlm.nih.gov/pubmed/35856436
http://dx.doi.org/10.3892/or.2022.8367
work_keys_str_mv AT liuzhuo liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma
AT zhoukunyan liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma
AT zengjian liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma
AT zhouxin liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma
AT lihuanyu liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma
AT pengke liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma
AT liuxiang liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma
AT lifeng liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma
AT jiangbin liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma
AT zhaoming liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma
AT matiexiang liverkinaseb1inexosomesinhibitsimmunecheckpointprogrammeddeathligand1andmetastaticprogressionofintrahepaticcholangiocarcinoma